FINWIRES · TerminalLIVE
FINWIRES

HKG:6185

3 stories mentioning HKG:6185Updated 21d ago

Every FINWIRES story that references HKG:6185, newest first.

Asia

CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine

CanSino Biologics (HKG:6185, SHA:688185) initiated a phase 1/2 trial of its 24-valent pneumococcal conjugate vaccine, a broad-spectrum shot designed to prevent infections caused by 24 pneumococcal serotypes, according to a Tuesday filing with the Hong Kong bourse.The trial will evaluate the vaccine in subjects aged two months and older for the prevention of pneumococcal infections, which can cause diseases such as pneumonia and meningitis.The new product could expand coverage beyond the company's existing 13-valent pneumococcal vaccine, which was approved in China in June 2025.The firm said there were currently no 24-valent pneumococcal conjugate vaccines available on the global market.

HKG:6185SHA:688185
Asia

CanSino Biologics Widens Loss in Q1

CanSino Biologics (HKG:6185, SHA:688185) widened its attributable loss in the first quarter of 2026 to 40.4 million yuan from 11.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Loss per share was 0.16 yuan, compared with 0.05 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 39% to 190.3 million yuan from 137.2 million yuan in the year-ago period, amid the company's expanding commercial product portfolio, increasing overseas presence, and robust sales of hte MCV4 vaccine.The vaccine manufacturer attributed the wider loss to a higher operating cost; a rise in selling, administrative, and R&D expenses; and a lower other income related to government grants and international funding support.

HKG:6185SHA:688185
Asia

CanSino Biologics Infant Combination Vaccine Approved in China

CanSino Biologics (HKG:6185) received Chinese regulatory approval for its infant combination vaccine, according to a Hong Kong bourse filing Sunday.Shares of the firm gained over 1% in morning trade Monday.China's National Medical Products Administration approved the company's DTcP vaccine Tripecia, which protects from diphtheria, tetanus, and pertussis for infants below 2 years old.CanSino said its vaccine is the first of its kind to be launched in China for infants.

HKG:6185

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:6185 in your portfolio
WheelAI
WheelAI
Analyze HKG:6185 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:6185